Cargando…

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3

BACKGROUND: High concentrations of both phosphate and fibroblast growth factor 23 (FGF23) observed in chronic kidney disease (CKD) are associated with an increased risk of cardiovascular morbidity and mortality. Pulse wave velocity (PWV) is a surrogate marker for cardiovascular events and all-cause...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouma-de Krijger, Annet, van Ittersum, Frans J, Hoekstra, Tiny, ter Wee, Pieter M, Vervloet, Marc G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	CKD-Mbd
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768309/ https://www.ncbi.nlm.nih.gov/pubmed/31584563 http://dx.doi.org/10.1093/ckj/sfz027

Ejemplares similares

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease
por: Ureña-Torres, Pablo A, et al.
Publicado: (2018)

Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): a case series
por: Russo, Domenico, et al.
Publicado: (2016)

Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients
por: Cianciolo, Giuseppe, et al.
Publicado: (2016)

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials
por: Caluwé, Rogier, et al.
Publicado: (2016)

Is progression of coronary artery calcification influenced by modality of renal replacement therapy? A systematic review
por: Jansz, Thijs T, et al.
Publicado: (2018)

Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation
por: Christiadi, Daniel, et al.
Publicado: (2018)

Multi-intervention management of calcific uremic arteriolopathy in 24 patients
por: Harris, Claire, et al.
Publicado: (2018)

Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients
por: Fouque, Denis, et al.
Publicado: (2018)

Is chronic kidney disease-mineral and bone disorder associated with the presence of endothelial progenitor cells with a calcifying phenotype?
por: Cianciolo, Giuseppe, et al.
Publicado: (2017)

Soluble klotho may be a marker of phosphate reabsorption
por: Tan, Sven-Jean, et al.
Publicado: (2017)

Placebo-controlled, randomized clinical trial of high-dose cholecalciferol in renal dialysis patients: effect on muscle strength and quality of life
por: Singer, Richard, et al.
Publicado: (2018)

Vitamin D, bone alkaline phosphatase and parathyroid hormone in healthy subjects and haemodialysed patients from West Africa: impact of reference ranges and parathyroid hormone generation assays on the KDIGO guidelines
por: Cavalier, Etienne, et al.
Publicado: (2018)

Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
por: Rottembourg, Jacques, et al.
Publicado: (2018)

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism
por: Sato, Tetsuhiko, et al.
Publicado: (2019)

Small steps towards the potential of ‘preventive’ treatment of early phosphate loading in chronic kidney disease patients
por: Bover, Jordi, et al.
Publicado: (2019)

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study
por: Rottembourg, Jacques, et al.
Publicado: (2019)

Sevelamer reduces endothelial inflammatory response to advanced glycation end products
por: Gregório, Paulo C, et al.
Publicado: (2018)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Fibroblast growth factor 23: are we ready to use it in clinical practice?
por: Bouma-de Krijger, Annet, et al.
Publicado: (2020)

Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease
por: van der Vorm, Lisa N, et al.
Publicado: (2019)

Renal artery intervention utilizing carbon dioxide angiography
por: Sag, Alan A, et al.
Publicado: (2017)

Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy
por: Brown, Stephanie A, et al.
Publicado: (2017)

Renal denervation using carbon dioxide renal angiography in patients with uncontrolled hypertension and moderate to severe chronic kidney disease
por: Hameed, Mohammed Awais, et al.
Publicado: (2017)

Patterns of progression of chronic kidney disease at later stages
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2018)

The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker
por: Canney, Mark, et al.
Publicado: (2018)

Frailty and chronic kidney disease: current evidence and continuing uncertainties
por: Nixon, Andrew C, et al.
Publicado: (2018)

A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records
por: Friberg, Leif, et al.
Publicado: (2018)

Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2017)

The metabolomic quest for a biomarker in chronic kidney disease
por: Davies, Robert
Publicado: (2018)

The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary
por: Pippias, Maria, et al.
Publicado: (2017)

Current trends in European renal epidemiology
por: Heaf, James
Publicado: (2017)

Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease
por: Vega, Almudena, et al.
Publicado: (2017)

Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis
por: Iyasere, Osasuyi, et al.
Publicado: (2018)

Clarifying the concept of chronic kidney disease for non-nephrologists
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Impact of a phone app on nephrology referral
por: Oliva-Damaso, Nestor, et al.
Publicado: (2018)

Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients
por: Lai, Silvia, et al.
Publicado: (2018)

Anticoagulant-related nephropathy: systematic review and meta-analysis
por: de Aquino Moura, Karolinny Borinelli, et al.
Publicado: (2019)

Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease
por: Hunt, Taylor V, et al.
Publicado: (2018)

Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1
por: Barbieri, Diego, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q4k11dt4tpblr210esr2q8m06c